Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/005096

International filing date: 06 December 2004 (06.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0328295.1
Filing date: 05 December 2003 (05.12.2003)

Date of receipt at the International Bureau: 24 January 2005 (24.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)

GB04/5096

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed P. Mahoney

Dated 23 December 2004

Patents Form 1/77

Patents Act 1977
(Rule 16)

1/77

08DEC03 E857634-1 002847
P01/7700 0.00-0328295.1

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

THE PATENT OFFICE
05 DEC 2003
RECEIVED BY HAND

1. Your reference — P70568GB01/JRH

2. Patent application number *(The Patent Office will fill in this part)* — 0328295.1 — 5 DEC 2003

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*

Muscagen Limited
12 Belgrave Court
25 Cowbridge Road East
Cardiff CF1 9BJ

Patents ADP number *(if you know it)* 8106221003

If the applicant is a corporate body, give the country/state of its incorporation — United Kingdom

4. Title of the invention

THERAPEUTIC COMPOUNDS

5. Full name of your agent *(if you have one)* — Haseltine Lake

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*

Imperial House
15-19 Kingsway
London WC2B 6UD

Patents ADP number *(if you know it)* — 34001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country	Priority application number *(if you know it)*	Date of filing *(day/month/year)*

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing *(day/month/year)*

8. Is a statement of inventorship and of right to a grant of patent required in support of this request? *(Answer "Yes" if:*
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Yes

Patent Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document.

Continuation sheets of this form	
Description	36
Claims(s)	11
Abstract	2
Drawing(s)	0

SV

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to a grant of patent *(Patents Form 7/77)*	
Request for preliminary examination and search *(Patents Form 9/77)*	1
Request for substantive examination *(Patents Form 10/77)*	
Any other documents *(please specify)*	

11. I/We request the grant of a patent on the basis of this application.

Haseltine Lake, Agents for the Applicants — Signature — Date: 2 December 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

NASH, David Allan — Tel: +44 (0) 117 910 3200 Fax:+44 (0) 117 910 3201

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*

b) *Write your answers in capital letters using black ink or you may type them.*

c) *If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*

d) *If you have answered `Yes' Patents Form 7/77 will need to be filed.*

e) *Once you have filled in the form you must remember to sign and date it.*

f) *For details of the fee and ways to pay please contact the Patent Office.*

THERAPEUTIC COMPOUNDS

Field of the Invention

This invention relates to muscarinic agonists with M_1 selectivity which are useful as agents for stimulating the cognitive functions of the brain.

Brief Description of the Invention

According to a first embodiment of the present invention, there is provided a compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is CH or nitrogen;

B is $-CH_2-$, $-CHF-$, $-CF_2-$, NR_4 or O, with the proviso that when A is N, B is $-CH_2-$, $-CHF-$ or $-CF_2-$;

G is oxygen or =N-CN,

R_1 is hydrogen or C_{1-6} alkyl;

R_2 is hydrogen; C_{1-10} alkyl optionally substituted with C_{1-6} alkoxy or halogen; aralkyl, a $-CH_2$-heterocycle or a $-CH_2-C_5$ cycloalkyl ring each of which may be optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is hydrogen; a cyclic alkyl radical containing from 3-6 carbon atoms or a C_1-C_6 alkyl;

R_4 is hydrogen or lower alkyl;

R_5 is a 5-membered unsaturated heterocyclic ring having one of the following structures:





where L and M are independently O or N (or NH where the circumstances require) with the proviso that both of L and M cannot be O; Y is S, CH, O or N (or NH where the circumstances require); X is C or N; and

R_6 is lower alkyl; hydrogen; arylamino optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl; aralkyl optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl; or a group of formula:



wherein n is an integer in the range from 1 to 4 and HET is a heterocyclic group optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

or R_5 may also be C_2-C_4-aralkyl (e.g. CH_2-CH_2-phenyl), -CH_2-O-R_7 where R_7 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_2-C_4 aralkyl (e.g. CH_2-CH_2-phenyl) which groups may be optionally substituted with fluoro or hydroxy; and

R_8 is hydrogen or aryl (optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

with the proviso that when either R_3 or R_8 is not hydrogen, the other is hydrogen.

In accordance with a second embodiment of the invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of the compound of the first embodiment.

In accordance with a third embodiment of the invention, there is provided a compound in accordance with the first embodiment of the invention for use as a medicament.

In accordance with a fourth embodiment of the invention, there is provided the use of a compound in accordance with the first embodiment of the invention in the manufacture of a medicament for the treatment of disorders caused by the malfunction of the acetylcholine or muscarinic systems.

In accordance with a fifth embodiment of the invention, there is provided a method for the treatment, prophylaxis and/or inhibition of disorders caused by the malfunction of the acetylcholine or muscarinic systems comprising the administration of a therapeutically effective amount of a compound in accordance with the first embodiment of the invention to a subject in need thereof.

Detailed Description of the Invention

In the embodiments of the invention,

G is preferably oxygen.

R_1 is preferably hydrogen or lower alkyl such as methyl. R_1 is most preferably hydrogen.

R_2 may be C_{1-8} alkyl, such as n-C_5H_{11}, or -CH_2-aryl, preferably -CH_2-C_6H_5 in which the aryl may be unsubstituted or substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl. Alternatively, R_2 may be -CH_2-C_5

cycloalkyl such as $-CH_2$-cyclopentane or $-CH_2$-cyclopenta-1,3-diene. Another preferred R_2 radical is $-CH_2$-heterocyclic aryl, for example $-CH_2$-benzoxazole, in which the $-CH_2$-heterocyclic aryl may be optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl. The invention includes within its scope other $-CH_2$-heterocyclic aryl groups such as $-CH_2$-benzodioxole, $-CH_2$-benzooxathiole, $-CH_2$-benzoimidazole, $-CH_2$-benzothiazole, $-CH_2$-benzodithiole $-CH_2$-pyridyl, $-CH_2$-pyrimidyl all of which may be optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl. The invention also includes within its scope other non-aromatic $-CH_2$-heterocyclic groups such as $-CH_2$-thiophene, $-CH_2$-furan, $-CH_2$-pyrrolidine, $-CH_2$-oxathiolane, $-CH_2$-thiazolidine, $-CH_2$-oxazolidine, $-CH_2$-dithiolane, $-CH_2$-dioxolane, $-CH_2$-imidazoline all of which may be optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl.

Also in accordance with the present invention but presently less preferred is $-CH_2$-naphthyl in which the naphthyl is unsubstituted or substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl.

R_3 is preferably hydrogen, cyclobutyl, cyclopropyl, methyl, ethyl, isopropyl, butyl, sec-butyl, more preferably hydrogen or cyclobutyl.

R_4 is preferably hydrogen.

R_5 is preferably one of the following 5-membered unsaturated heterocyclic ring structures:



where R_6 is preferably methyl, aralkyl, arylamino, aralkyl substituted by one or more halo and having a methylene group linking the aryl to the unsaturated 5-membered ring, aralkyl substituted by one or more halo and having an ethylene group linking the aryl to the unsaturated 5-membered ring, R_6 is more preferably phenyl, phenylamino substituted by one or more halo (e.g. chloro), phenylmethyl substituted by one or more halo (e.g chloro), or phenethyl substituted by one or more halo (e.g. chloro), R_6 is most preferably a meta chloro-substituted phenylamino, a meta chloro-substituted phenylmethyl or a meta chloro-substituted phenethyl.

More preferred at present amongst the above unsaturated 5 membered heterocyclic rings are:

5-methyl-1,2,4-thiadiazol-3-yl;

5-methyl-1,2,4-oxadiazol-3-yl;

5-methyl-1,4-oxazol-3-yl;

4-methyl-1,3-oxazol-2-yl;

5-methyl-1,3-oxazol-2-yl;

5-methyl-1,4-oxazol-2-yl.

When R_5 is $-CH_2-O-R_7$, R_7 is preferably $-C_{2-4}$-aralkyl, more preferably $-CH_2-CH_2$-aryl, most preferably $-CH_2-CH_2$-phenyl.

R_8 is preferably hydrogen, phenyl or halo-substituted phenyl, more preferably fluoro-substituted phenyl and most preferably 3,5-difluorophenyl.

In one aspect of the first embodiment, A is CH; B is $-CH_2-$; G is oxygen; R_1 is hydrogen; R_2 is C_{1-10} alkyl, for example n-C_5H_{11}, or $-CH_2$-aryl, for example $-CH_2-C_6H_5$ (optionally substituted as described below), or $-CH_2$-heterocyclic aryl, for example $-CH_2$-benzoxazole (optionally substituted as described below). R_3 is cyclobutyl or H; R_5 is one of the preferred or more preferred 5-membered unsaturated heterocyclic ring structures specified above; and R_8 is H or phenyl (optionally substituted with halo). Examples of compounds falling within this definition are:













In another aspect, A is CH; B is O; G is oxygen; R_1 is hydrogen; R_2 is C_{1-10} alkyl, for example n-C_5H_{11}, or -CH_2-aryl, for example -CH_2-C_6H_5 (optionally substituted as described below), -CH_2-$C_{10}H_7$ (optionally substituted as described below) or -CH_2-heterocyclic aryl, for example -CH_2-benzoxazole (optionally substituted as described below). R_3 is cyclobutyl or H; R_5 is one of the preferred or more preferred 5-membered unsaturated heterocyclic ring structures specified above, -CH_2-O-CH_3

or $-CH_2-O-CH_2-CH_2-C_6H_5$; and R_8 is H or phenyl (optionally substituted with halo). Examples of compounds falling within this definition are:













In another aspect, A is CH; B is NH; G is oxygen; R_1 is hydrogen; R_2 is C_{1-10} alkyl, for example n-C_5H_{11}, or -CH_2-aryl, for example -CH_2-C_6H_5 (optionally substituted as described below),-CH_2-$C_{10}H_7$ (optionally substituted as described below),-CH_2-heterocyclic aryl, for example -CH_2-benzoxazole, -CH_2-pyridyl or -CH_2-pyrimidyl (optionally substituted as described below), a -CH_2-heterocyclic group (optionally substituted as described below), or a -CH_2- substituted C_5 cycloalkyl (optionally substituted as described above); R_3 is cyclobutyl or H; R_4 is hydrogen; R_5 is one of the preferred or more preferred 5-membered unsaturated heterocyclic ring structures specified above, -CH_2-O-CH_3 or -CH_2-O-CH_2-CH_2-C_6H_5; and R_8 is H or phenyl (optionally substituted with halo). Examples of compounds falling within this definition are:









In another aspect, A is N; B is $-CH_2-$; G is oxygen; R_1 is hydrogen; R_2 is C_{1-10} alkyl, for example n-C_5H_{11}, or $-CH_2$-aryl, for example $-CH_2C_6H_5$ (optionally

substituted as described below), $-CH_2-C_{10}H_7$ (optionally substituted as described below) or $-CH_2$-heterocyclic aryl for example $-CH_2$-benzoxazole, CH_2-pyridyl or CH_2-pyrimidyl (optionally substituted as described below), a $-CH_2$-heterocyclic group (optionally substituted as described below), or a $-CH_2-$ substituted C_5 cycloalkyl (optionally substituted as described above); R_3 is cyclobutyl or H; R_5 is one of the preferred or more preferred 5-membered unsaturated heterocyclic ring structures specified above; and R_8 is H or phenyl (optionally substituted by halo). Examples of compounds falling within this definition are:











In another aspect, A is N; B is $-CH_2-$; G is oxygen; R_1 is hydrogen; R_2 is C_{1-10} alkyl, for example n-C_5H_{11}, or $-CH_2$-aryl, for example $-CH_2-C_6H_5$ (optionally substituted as described below), or $-CH_2$-heterocyclic aryl, for example $-CH_2$-benzoxazole, CH_2-pyridyl or CH_2-pyrimidyl (optionally substituted as described below), a $-CH_2$-heterocyclic group (optionally substituted as described below), or a $-CH_2-$ substituted C_5 cycloalkyl (optionally substituted as described above); R_3 is cyclobutyl or H; R_5 is $-CH_2-O-CH_3$; and R_8 is H or phenyl (optionally substituted by halo). Examples of compounds falling within this definition are:







5







In another aspect, A is N; B is $-CH_2-$; G is oxygen; R_1 is hydrogen; R_2 is C_{1-10} alkyl, for example n-C_5H_{11}, or $-CH_2$-aryl, for example $-CH_2-C_6H_5$ (optionally substituted as described below), $-CH_2-C_{10}H_7$ (optionally substituted as described below) or $-CH_2$-heterocyclic aryl for example $-CH_2$-benzoxazole, $-CH_2$-pyridyl or $-CH_2$-pyrimidyl (optionally substituted as described below) or a $-CH_2$-heterocyclic group (optionally substituted as described below); R_3 is hydrogen or cyclobutyl; R_5 is one of the preferred or more preferred 5-membered unsaturated heterocyclic ring structures specified above; and R_8 is phenyl,3,5-difluorophenyl or H. Examples of compounds falling within this definition are:

















In the present context alkyl may be straight or branched. Where the alkyl is C_{1-6} alkyl, this may for example be methyl, ethyl, propyl, isopropyl, butyl, tert. butyl, pentyl or hexyl. The term "lower alkyl" designates C_{1-4} alkyl which may be straight or branched, such as methyl, ethyl, propyl, isopropyl, butyl or tert.butyl.

The term "alkenyl" designates a C_2-C_6 straight or C_3-C_6 branched alkyl group which contains a double bond, such as 2-propenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-methyl-2-propenyl or 3-methyl-2-butenyl. The term "haloalkenyl" designates an alkenyl group as defined above which may be substituted by one or more halo e.g. F, Cl, Br or I.

The term "alkynyl" designates a C_2-C_6 straight or C_3-C_6 branched alkyl group containing a triple bond, such as 2-propynyl, 2-butynyl, 2-pentynyl, 2-hexynyl or 4-methyl-2-pentynyl. The term "haloalkynyl" designates

an alkynyl group as defined above which may be substituted by one or more halo e.g. F, Cl, Br or I.

The term "aralkyl" designates a lower alkyl group (as herein defined) which, in turn, may be substituted with an aryl group, preferably a phenyl, heterocyclic aryl or naphthyl group which in turn may be substituted, for example by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl. Preferred aralkyl are benzyl, 1- and 2-phenylethyl, 1-, 2- and 3-phenylpropyl, 1-methyl-1-phenylethyl, 6-ethyl benzoxazole and $-CH_2$-naphthyl. Where the aryl group, preferably phenyl, heterocyclic aryl or naphthyl group, of the aralkyl is substituted with haloalkyl (preferably C_{1-4} alkyl), halogen, lower alkyl, or C_{1-6} alkoxy, they may be mono-, di- or tri-substituted and when they are di-or tri-substituted the substituents may be the same or different. Preferred substituents on the phenyl are $-CF_3$, chloro, bromo, C_{2-6} alkyl and C_{4-8} alkoxy. Preferred substituents on the naphthyl are $-CF_3$, chloro, bromo, C_{1-4} alkyl (such as methyl), and C_{3-7} alkoxy.

The term "heterocycle" designates a heterocyclic group, which may be a heterocyclic aryl group as described above or non-aromatic heterocyclic group each of which may be substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl. The preferred heterocycles of the invention are 5 membered rings optionally substituted as described above.

The term "halogen" designates F, Cl, Br, or I; Cl, Br and F are preferred.

The term "alkoxy" denotes a C_1-C_6 straight or C_3-C_6 branched alkoxy group. Examples of such groups are methoxy, ethoxy, propoxy, butoxy, pentoxy, hexoxy, 2-

methyl ethoxy, 2-ethyl propoxy and 1-ethyl-2-methyl-propoxy.

The term "haloalkoxy" designates an alkoxy group as defined above which may be substituted by one or more halo e.g. F, Cl, Br or I.

Examples of suitable salts include inorganic and organic acid addition salts such as hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate, tartrate, oxalate or similar pharmaceutically-acceptable inorganic and organic acid addition salts.

The compounds of the invention exist in geometrical and/or optical isomers. The present invention encompasses all enantiomers and mixtures thereof. Preferred is the isomer shown below:



The compounds of the invention are selective m_1-muscarinic receptor agonists and therefore useful in methods for the treatment of disorders, such as Alzheimer's disease, caused by malfunction of the acetylcholine (AcCh) or muscarinic system, by administering a non-toxic effective amount thereof to a mammalian, normally human, subject.

Compounds of the invention may be made by methods known in the art.

Thus, for example, compounds in which A is N, B is $-CH_2-$ and R_5 is $-CH_2-O-Me$ may be made in accordance with the following synthetic pathway:

Reaction Scheme 1



Steps 1 & 2

Treatment of allyl alcohol 1 with hydrochloric acid in methanol gives the known ether 2, which is converted to the known dibromide 3, by addition of bromine.

Steps 3 & 4

Nucleophilic displacement by excess benzylamine in the presence of a high boiling solvent, under an inert atmosphere yields the diamine 4. In the presence of air the geminal diamine 5 is formed. This may be reconverted to the diamine 4 by hydrogenolysis. In a

similar manner, reaction with *p*-methoxybenzylamine gives analogous products which may be used in subsequent reactions in an identical way. The *p*-methoxybenzylamine derivatives have the advantage that they are cleaved more easily than the benzylamine derivatives (cf. step 6).

Step 5

Reaction with ethyl chloroacetate or a range of other α-haloesters (eg α-bromo- or α-iodoesters bearing other alkyl substituents) yields the piperidinone 6, plus the regioisomer together with diacylated and dialkylated products. Reaction at -10°C, in methylene chloride, with 1.2 equivalents of α-chloroacetyl chloride gives a mixture from which the desired isomer 6 can be isolated in 70% yield. The piperidinone 6, serves as a common starting material for all subsequent reactions. Reactions shown in brackets (Steps 6 & 9) are used as appropriate according to the substituents/protecting groups present. The following examples illustrate the general methodology.

Steps 6-9(a) Compounds 7-11 where R_1= Bn or p-MeOBn; R_2 = any alkyl, aryl or benzyl, R_3 = any alkyl, aryl or benzyl

Cleavage of the amidic benzylamine substituent with sodium in liquid ammonia gives the amide 7 (R_1 = H), which is treated sequentially with sodium hydride in DMSO (or other strong bases) and the haloamide 8 (X = preferably Cl, but also Br or I) to give the tertiary amide 9. Reaction with an organometallic reagent such as a Grignard or organolithium reagent gives the aminol 10, which spontaneously cyclises and upon acidification yields the salt 11.

(b) Compounds 7-11 where R_1 is H; R_2 is any alkyl, aryl or benzyl, R_3 is H or any alkyl, aryl or benzyl

Hydrogenolysis of the benzylic amine yields a secondary amine, which is protected as the silyl ether with tri-isopropylsilyl-, *t*-butyldimethylsilyl- or *t*-butyldiphenylsilyl- trifluoromethanesulfonate. Cleavage of the amidic benzylic substituent with sodium in liquid ammonia yields the secondary amide 7 (R_1 = $^{i}Pr_3Si$, $^{t}BuMe_2Si$ or $^{t}BuPh_2Si$). Subsequent reactions, follow the sequence outlined above under (a), except that deprotection with a nucleophilic fluoride source is required in Step 9. This is typically tetrabutylammonium fluoride, cesium fluoride or another comparable reagent known in the prior art.

(c) Compounds 7-11 where R_1 is any alkyl, aryl or benzyl; R_2 is any alkyl, aryl or benzyl, R_3 is H or any alkyl, aryl or benzyl

This pathway follows the sequence under (b) above, except that in step 6b, the secondary amine is converted to a tertiary amine by reaction with an alkylating reagent (eg. haloalkane or benzylic halide) or an arylating reagent (eg ArBr, Cu or ArCl, $PdCl_2(PAr_3)_2$ with the aminostannane). No deprotection is required in step 9.

Compounds in which A is CH, B is O and R_5 is 4-methyloxazol-2-yl or $-CH_2-O-Me$ may be made in accordance with the following alternative synthetic pathways:

Reaction Scheme 2

M_1-Muscarinic Receptor Agonist Synthetic Route:



Scheme 1. *Reagents:* i. Br_2, MeOH; ii. KCO_2H, MeOH; iii. TBSCl, Imidazole, DCM; iv. $(EtO)_2PCH_2CO_2Et$, NaH, THF; v. DIBAL-H, THF; vi. CF_3CN, NaH, THF; vii. xylene; viii. $NaBH_4$, EtOH; ix. CbzCl, Et_3N, DCM; x. O_3, PPh_3, DCM; xi. CH_2=CMeMgBr, THF; xii. *m*CPBA, DCM; xiii. TMP, *n*-BuLi, THF; xiv. BnBr, NaH, THF; xv. RI, NaH, THF; xvi. CBr_4, PPh_3, MeCN; xvii. RLi or RNa, THF; xviii. a. BH_3, THF; b. EtOH, NaOAc, H_2O_2; xix. TBAF, THF; xx. MsCl, Et_3N, DCM; xxi. $BnNH_2$; xxii. Pd/C, HCO_2H, MeOH; xxiii. CH_2=CMeMgBr, THF; xxiv. BnBr, NaH, THF; xxv. O_3, PPh_3, DCM; xxvi. KHMDS, $PhN(Tf)_2$, THF; xxvii. HC=CXLi or HC=CXMgBr, THF; xxviii. R'X, Pd(0), THF; xxix. Dess Martin periodinane, DCM; xxx. 2-methyl-2-butene, $NaClO_2$, NaH_2PO_4, *t*-BuOH/water; xxxi. *i*-BuOCOCl, NMM, 2-aminopropanol, THF; xxxii. Dess Martin periodinane, DCM; xxxiii. 2,6-di-*t*-Butyl-4-methylpyridine, PPh_3, $Cl_2BrCCCl_2Br$, DBU, DCM, CH_3CN.

M1-Muscarinic Receptor Agonist Synthesis

The protected α-amino-aldehyde **4** was identified as a key intermediate in the synthesis of the target molecules **7** and **10** since stereoselective vinyl Grignard addition followed by functional group modification and cyclisation would lead to the required piperidines. The introduction of the tertiary amino group into the aldehyde **4** was as a key step in the synthesis which was to be accomplished by rearrangement of an allylic trifluoroacetimidate.

The protected hydroxyketone **2** was prepared from the commercially available cyclobutyl methyl ketone **1** by bromination, hydrolysis of the bromoketone so obtained and protection. Condensation of the ketone **2** with triethyl phosphonoacetate followed by reduction using diisobutylaluminium hydride gave the corresponding allylic alcohol which was converted into the trifluoroacetimidate **3** using trifluoroacetonitrile. On reflux in xylene this trifluoroacetimidate rearranged to the isomeric tertiary trifluoroacetamide which was taken through to the aldehyde **4** by removal of the trifluoroacetyl group using sodium borohydride, *N*-protection and ozonolysis.

Addition of prop-2-enyl magnesium bromide was stereoselective and on work-up was accompanied by cyclisation to give a carbamate which was converted into the intermediate **5** by epoxidation, lithium 2,2,6,6-tetramethylpiperidide induced epoxide-allylic alcohol rearrangement and *N*- protection using sodium hydride benzyl bromide.

The next steps involved modification of the hydroxyl groups to give access to various side-chains.

Thus, for example, *O*-methylation using methyl iodide and sodium hydride gave the methyl ether **6** (R = OMe) which was taken through to the target **7** (R = OMe) by hydroboration with an oxidative work-up, removal of the silyl protecting group, mesylation of both hydroxyl groups, and displacement of the mesylates followed by hydrogenolysis of the *N*-benzyl group.

In an approach to the analogue with a 4-methyloxazol-2-yl side chain **10** (R′ = 4-methyloxazol-2-yl), the alcohol **5** was oxidised to the corresponding acid over two steps, and the acid converted into its amide using 2-aminopropanol. Cyclisation was achieved by oxidation to the aldehyde using the Dess Martin periodinane followed by dehydration to give **9** (R′ = 4-methyloxaxol-2-yl). However, in this case, conversion to the target **10** (R′ = 4-methyloxazol-2-yl) was inefficient because of competing elimination of the carbamate after the hydroboration step. Ozonolysis of the alkene **8** (X = Me) gave the corresponding ketone which was converted into its enol triflate **8** (X = OTf) for palladium cataylsed coupling with aryl halides.

Compounds in which A is CH, B is N and R_5 is $-CH_2-O-Me$ may be made in accordance with the following synthetic pathway:

Reaction Scheme 3



Step 1

The alkylation of the piperidinone 1 (R_1 = Bn; R_3 = H) using sodium hydride and dimethylcarbonate has been reported (S. Singh, G. P. Basnadjian, K. S. Avor, B. Pouw, T. W. Seale, Synthesis and ligand binding studies of 4'-iodobenzoyl esters of tropanes and piperidines at the dopamine transporter, J. Med. Chem., 1997, 40, 2474-2481). Moreover the compound 2 (R_1 = Bn; R_3 = H) has been reported to be commercially available (H.-J. Altenbach and G. Blanda, A novel building block for the synthesis of isofagomin analogues, Tetrahedron: Asymmetry, 1998, 9, 1519-1524) and has been converted

into the compound 4 (R_1= Bn, R_3 = H). Adaption of the known routes to these compounds enables the synthesis of compounds 1 and 2 in which R_1 = alkyl, benzyl and CH_2-heteroaromatic.

Step 2

Generation of the dianion of the β-ketoester 2, with LDA (lithium di-isopropylamide) or a comparable strong base and treatment with an electrophilic alkylating reagent (R_3X, X = Cl, Br, I, OTs, OMs or a comparable nucleofuge), enables the synthesis of compounds 3 (R_3 = n-alkyl, benzyl, CH_2-heteroaromatic, or allyl or derivatives thereof). In the cases in which R_3 cannot act as a suitable alkylating agent (eg. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, isopropyl and other secondary and tertiary substituents), the desired compounds are prepared by an alternative route. Thus a ketone ($CH_3COCH_2R_3$) is treated with formaldehyde (or a synthetic equivalent) and ammonia or an appropriate amine (eg. R_1NH_2) to give the piperidinone 1 directly.

Step 3

Formation of the *p*-toluenesulfonylhydrazone with *p*-toluenesulfonylhydrazine and treatment with three equivalents of base, followed by lithium aluminium hydride reduction gives the desired compound 4 (R_3= H; Shapiro reaction, cf. Altenbach &. Blanda, as above). However when R_3 is not hydrogen, it is more advantageous to reduce the ketone with sodium borohydride and to effect β-elimination with *p*-toluenesulfonyl chloride to give the α,β-unsaturated ester. Treatment with LDA generates the enolate which is reprotonated at the a-position with *t*-butyl bromide (or a comparable proton source) to give the β,γ-unsaturated ester, which in turn is reduced with lithium aluminium hydride to give the homoallylic alcohol 4.

Steps 4 & 5

The homoallylic alcohol 4 is treated with potassium *t*-butoxide and butyl lithium at low temperatures in non-polar solvents to generate the potassium alkoxide. This is reacted in turn with a toluene solution of phosgene and an alkali or alkaline metal azide salt to yield the acyl azide 5. Alternatively the potassium alkoxide of the homoallylic alcohol 4 is treated with azidocarbonic acid methyl ester. Warming to room temperature or slightly higher effects cyclisation to yield the triazoline 6.

Step 6

Reductive cleavage of the triazoline 6 to the aminourethane 7 may be achieved using a variety of conditions. Hydrogenolysis with hydrogen catalysed by palladium or platinium is cheapest and most effective, however if R_1= Bn and it is desirable for this group to be retained, triphenylphosphine or a comparable trivalent phosphorus reagent plus water or ammonium hydroxide or sodium hydroxide is preferable. Reduction with lithium aluminium hydride yields 10 (R_1 & R_3 as 6; R_2 = H; R_4 = CH_3).

Step 7

The aminourethane 7 may be alkylated on the primary amino group with an electrophilic reagent R_2X, within the usual scope of such reactions (R_2 = n-alkyl, benzyl, CH_2-heteroaromatic, or allyl or derivatives thereof; X = Cl, Br, I, OTs, OMs or a comparable nucleofuge).

Steps 8 and 9

Cleavage of the urethane group with refluxing concentrated sodium hydroxide or concentrated hydrochloric acid containing a trace of p-toluenesulfonic acid yields the primary amine 9, which may be alkylated (R_4) as in step 7. In this case the regioselectivity is poorer and some multiple alkylation products are also formed.

Step 10

Treatment with potassium t-butoxide and no more than one equivalent of dimethylsulfate yields the methyl ether 11.

Step 11

Treatment with phosgene, diphosgene or triphosgene or any of a number of synthetic equivalents, plus a base yields the urea, which is converted to the salt 12, by treatment with an acid. If desired, the benzyl group (R_1) may be removed by hydrogenolysis using hydrogen and platinium or palladium catalysts and the secondary amine so formed alkylated with an electrophilic reagent R4X, within the usual scope of such reactions (R_1 = n-alkyl, benzyl, CH_2-heteroaromatic, or allyl or derivatives thereof; X = Cl, Br, I, OTs, OMs or a comparable nucleofuge).

Compounds in which A is CH, B is N and R_5 is a 5-membered heterocyclic ring may be made following the pathway above for compounds in which A is CH, B is N and R_5 is $-CH_2-O-R_7$ starting with compound 10 and applying step 11 gives compounds 12 in which the lower most substituent is a hydroxyl group instead of a methyl ether. The hydroxyl group may be oxidised to a carboxylic acid and converted to an ester as before. The practicality of step 11 in this specific context depends on the substituents R_1, R_2 and R_4 on the amine groups. Compound 10 may be temporarily protected by reaction of the alkoxide (as in the original route, step 10), but with benzyl bromide to give a benzyl ether (11 Me = Bn). Step 11 follows as before to give 12 (Me = Bn). The benzyl group is then removed using hydrogen and platinium on charcoal to give 12 (Me = H), which can be oxidised as above. In this alternative pathway, the designation 12 refers to the free amine rather than the ammonium salt shown in the scheme and

the procedure is not applicable to the case where R_1, R_2 or R_4 = Bn.

Similarly, compounds in which A is CH, B is O, G is O, R_2 is benzyl, R_3 is H, R_5 is $-CH_2-O-CH_3$ or oxazole and R_8 is phenyl may be made by the following reaction scheme:

Reaction Scheme 4



It will be appreciated that the above reaction scheme may be generalised or varied as appropriate in order to produce additional compounds in accordance with the first embodiment of the invention. This variation would be within the ability of one skilled in the art.

M_1 receptor activity of a compound of the invention may be examined with the rabbit vas deferens using a method developed from that described previously (Dorje F, Rettenmayr N, Mutschler E and Lambrecht G, Eur J Pharmacol 1991,203,417-420). The tissue is stimulated electrically to contract and the conditions are optimized so that M_1 receptor agonists produce a concentration-related inhibition of contraction height. Any activity at M_2 receptors is indicated by an increase in the contraction height. M_2 receptor activity may also be recorded from increases in contraction of the guinea-pig paced left atria. M_3 receptor activity is measured from the contraction of the guinea-pig ileum. Other methods for analysing M_1 receptor activity may be employed, such as those described in EP-A-0336555 and EP-A-0384288 (the disclosures of which are hereby incorporated by reference to the extent possible under the relevant national law).

In accordance with the second embodiment, the compounds of the present invention, together with a conventional adjuvant, carrier, or diluent, and if desired in the form of a pharmaceutically-acceptable acid addition salt thereof, may be placed in the form of pharmaceutical compositions and unit dosages thereof, and in such form may be employed as solids, such as tablets or filled capsules, or liquids, such as solutions, suspensions, emulsions, elixirs, or capsules filled with the same, all for oral use, in the form of suppositories for rectal administration; or in the form of sterile injectable solutions for parenteral (including subcutaneous) use. Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any

suitable effective muscarinic cholinergic agonistic amount of the active ingredient commensurate with the intended daily dosage range to be employed. Tablets containing ten (10) milligrams of the active ingredient or, more broadly, one (1) to hundred (100) milligrams, per tablet, are accordingly suitable representative unit dosage forms. The compounds of this invention can thus be used for the formulation of pharmaceutical preparations, e.g. for oral and parenteral administration to mammals including humans, in accordance with conventional methods of galenic pharmacy.

Conventional excipients are such pharmaceutically acceptable organic or inorganic carrier substances suitable for parenteral or enteral application which do not deleteriously react with the active compounds.

Examples of such carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, gelatine, lactose, amylase, magnesium stearate, talc, silicic acid, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, hydroxymethylcellulose and polyvinylpyrrolidone.

The pharmaceutical preparations can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.

For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.

Ampoules are convenient unit dosage forms.

Tablets, dragees or capsules having talc and/or a carbohydrate carrier or binder or the like, the carrier preferably being lactose and/or corn starch and/or

potato starch, are particularly suitable for oral application. A syrup, elixir or the like can be used in cases where a sweetened vehicle can be employed.

Generally, the compounds of this invention are dispensed in unit form comprising 1-100 mg in a pharmaceutically acceptable carrier per unit dosage.

The dosage of the compounds according to this invention is 1-100 mg/day, preferably 10-70 mg/day, when administered to patients, e.g. humans, as a drug.

A typical tablet which may be prepared by conventional tabletting techniques contains:

Active compound	5.0 mg
Lactosum	67.8 mg Ph.Eur.
Avicel®	31.5 mg
Amberlite®	1.0
Magnesli stearas	0.25 mg Ph.Eur.

In accordance with the third, fourth and fifth embodiments, the compounds of the invention are useful in the treatment and manufacture of medicaments for the treatment of symptoms related to a reduction of the cognitive functions of the brain of mammals, when administered in an amount effective for stimulating the cognitive functions of the forebrain and hippocampus. The important stimulating activity of the compounds of the invention includes both activity against the pathophysiological disease, Alzheimer's disease, as well as against normal degeneration of brain function.

The compounds of the invention may accordingly be administered to a subject, e.g. a living animal body, including a human, in need to stimulation of the cognitive functions of the forebrain and hippocampus, and if desired in the form of a pharmaceutically-acceptable acid addition salt thereof (such as hydrobromide, hydrochloride, or sulfate, in any event

prepared in the usual or conventional manner, e.g. evaporation to dryness of the free base in solution together with the acid) ordinarily concurrently, simultaneously, or together with a pharmaceutically-acceptable carrier or diluent, especially and preferably in the form of a pharmaceutical composition thereof, whereof by oral, rectal, or parenteral (including subcutaneous) route, in an effective forebrain and hippocampus stimulating amount, and in any event an amount which is effective for improving the cognitive function of mammals due to their muscarinic cholinergic receptor agonistic activity.

Suitable dosage ranges are 1-100 milligrams daily, 10-100 milligrams daily, and especially 30-70 milligrams daily, depending as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and the preference and experience of the physician or veterinarian in charge.

Examples

The invention is further illustrated by the following non-limiting example.

Example 1



3-Benzyl-3a-cyclobutyl-7-methoxymethyl-2-oxo-octahydro-oxazolo[4,5-c]pyridin-5-ium

The above compound was synthesised by the method of reaction scheme 2 above. The compound was characterised by IR spectroscopy.

Pharmacology

Functional assays of M1 receptor activity

Initial evaluation of the test compound is by assay of functional tissue responses. This has the advantage that it readily discriminates between agonist, partial agonist and antagonist activity.

M1 - Vas deferens preparations

Male New Zealand white rabbits (1.47-3.4 Kg) are killed by a blow to the back of the head and vasa deferentia removed, dissected free of connective tissue and divided into prostatic and epididmyal portions. Each segment is mounted on a tissue holder and passed through two ring electrodes (5mm apart). They are immersed in a modified low Ca^{2+} Krebs solution at 32+/-0.5°C and gassed with 5% CO_2 in oxygen. Yohimibine (1.0mM) is present throughout to block prejunctional a2-adrenoceptors. The upper end of the tissue is attached by cotton thread to an isometric transducer (MLT020, ADInstruments). Tissues are left to equilibrate for at least 45 min at passive force of 0.75-1g. Field stimulation is then applied by repeated application of single pulses (30V, 0.05Hz,0.5ms). Isometric tension is recorded by computer at a sampling rate of 100Hz, using Powerlab/200 (ADInstruments) software and MacLab bridge amplifiers.

M2 - Guinea-pig atria

Guinea-pigs are killed by a blow to the back of the head and left atrium removed. The atrium is secured to a pari of stainless steel electrodes by means of a cotton thread and immersed in the organ bath containing gassed Krebs soution with normal Ca^{2+} at 32+/-0.5°C. Atria are paced at 2Hz with square-wave pulses of 0.5ms pulse width. Isometric contractions are recorded by computer or polygraph.

M3 - Guinea-pig ileum

Sections (2cm) are cut from the ilium of the killed guinea-pigs, 10cm from the ileo-caecal junction. One end is attached to a tissue holder/aerator and the other end via a cotton thread to an isometric transducer. The tissue is immersed in gassed normal Ca^{2+} Krebs solution at 32+/-0.5°C. A resting tension of 0.5g is applied and isometric contractions measured by computer or polygraph.

Agonist concentration-response curves

Following at least 30 min equilibration to allow twitches or tension to stabilize, cumulative concentration-response curves for the muscarinic agonists are constructed. The concentration is increased in half logarithmic increments after the contraction in the presence of each concentration has plateaued. Steady-state contractions at each concentration are measured and the inhibition expressed as a percentage of the baseline twitch height in atria and vas deferens or as the maxi contraction in the ileum. EC50 values for the muscarinic agonists are determined from individual curves as the molar concentration required for 50% inhibition of twitch height or the 50% maximum contraction (ileum). Geometric mean EC50 values and their 95% confidence limits are calculated.

It was found that the compound of Example 1 was a 50% partial M1 agonist with a potency (EC50 value) of 10^{-7}M.

CLAIMS

1. A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is CH or nitrogen;

B is $-CH_2-$, $-CHF-$, $-CF_2-$, NR_4 or O, with the proviso that when A is N, B is $-CH_2-$, $-CHF-$ or $-CF_2-$;

G is oxygen or =N-CN,

R_1 is hydrogen or C_{1-6} alkyl;

R_2 is hydrogen; C_{1-10} alkyl optionally substituted with C_{1-6} alkoxy or halogen; aralkyl, a $-CH_2$-heterocycle or a $-CH_2-C_5$ cycloalkyl ring each of which may be optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is hydrogen; a cyclic alkyl radical containing from 3-6 carbon atoms or a C_1-C_6 alkyl;

R_4 is hydrogen or lower alkyl;

R_5 is a 5-membered unsaturated heterocyclic ring having one of the following structures:



where L and M are independently O or N (or NH where the circumstances require) with the proviso that both of L

and M cannot be O; Y is S, CH, O or N (or NH where the circumstances require); X is C or N; and

R_6 is lower alkyl; hydrogen; arylamino optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl; aralkyl optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl; or a group of formula:



wherein n is an integer in the range from 1 to 4 and HET is a heterocyclic group optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

or R_5 may also be C_2-C_4-aralkyl, $-CH_2-O-R_7$ where R_7 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_2-C_4 aralkyl which groups may be optionally substituted with fluoro or hydroxy; and

R_8 is hydrogen or aryl (optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

with the proviso that when either R_3 or R_8 is not hydrogen, the other is hydrogen.

2. A compound according to claim 1, in which

G is O;

R_1 is H or lower alkyl;

R_2 is C_{1-8} alkyl, $-CH_2$-aryl or a $-CH_2$-substituted heterocycle each of which may be optionally

substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is hydrogen, cyclobutyl, cyclopropyl, methyl, ethyl, isopropyl, butyl, sec-butyl;

R_4 is hydrogen;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is methyl, aralkyl, arylamino, aralkyl substituted by one or more halo and having a methylene group linking the aryl to the unsaturated 5-membered ring, aralkyl substituted by one or more halo and having an ethylene group linking the aryl to the unsaturated 5-membered ring;

R_8 is hydrogen, phenyl or halo-substituted phenyl.

3. A compound according to claim 2, wherein

R_1 is H;

R_2 is $-CH_2$-aryl optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is hydrogen or cyclobutyl;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is phenyl, phenylamino substituted by one or more halo, phenylmethyl substituted by one or more halo, or phenethyl substituted by one or more halo;

R_8 is hydrogen or a fluoro-substituted phenyl.

4. A compound according to claim 3, wherein

R_2 is $-CH_2-C_6H_5$ or $-CH_2$-heterocyclic aryl each of which may be optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is H;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



R_6 is a meta chloro-substituted phenylamino, a meta chloro-substituted phenylmethyl or a meta chloro-substituted phenethyl;

R_8 is 3,5-difluorophenyl.

5. A compound according to claim 1, wherein

A is CH;

B is $-CH_2-$;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-10} alkyl or $-CH_2$-aryl (optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is methyl, aralkyl, arylamino, aralkyl substituted by one or more halo and having a methylene group linking the aryl to the unsaturated 5-membered ring, aralkyl substituted by one or more halo and having an ethylene group linking the aryl to the unsaturated 5-membered ring; and

R_8 is H or phenyl (optionally substituted with halo).

6. A compound according to claim 1, in which A is CH;

B is O;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-10} alkyl, $-CH_2$-aryl(optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H;

R_5 is $-CH_2-O-CH_3$, $-CH_2-O-CH_2-CH_2-C_6H_5$ or one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is methyl, aralkyl, arylamino, aralkyl substituted by one or more halo and having a methylene group linking the aryl to the unsaturated 5-membered ring, aralkyl substituted by one or more halo and having an ethylene group linking the aryl to the unsaturated 5-membered ring; and

R_8 is H or phenyl (optionally substituted with halo).

7. A compound according to claim 1, wherein

A is CH;

B is NH;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-10} alkyl, $-CH_2$-aryl, a $-CH_2$-heterocyclic group or a $-CH_2$-substituted C_5 cycloalkyl (optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H;

R_4 is hydrogen;

R_5 is $-CH_2-O-CH_3$, $-CH_2-O-CH_2-CH_2-C_6H_5$ or one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is methyl, aralkyl, arylamino, aralkyl substituted by one or more halo and having a methylene group linking the aryl to the unsaturated 5-membered ring, aralkyl substituted by one or more halo and having an ethylene group linking the aryl to the unsaturated 5-membered ring; and

R_8 is H or phenyl (optionally substituted with halo).

8. A compound according to claim 1, wherein

A is N;

B is $-CH_2-$;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-10} alkyl, $-CH_2$-aryl, a $-CH_2$-heterocyclic group or a $-CH_2$-substituted C_5 cycloalkyl (optionally substituted one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is methyl, aralkyl, arylamino, aralkyl substituted by one or more halo and having a methylene group linking the aryl to the unsaturated 5-membered ring, aralkyl substituted by one or more halo and having an ethylene group linking the aryl to the unsaturated 5-membered ring; and

R_8 is H or phenyl (optionally substituted with halo).

9. A compound according to claim 1, wherein

A is N;

B is $-CH_2-$;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-10} alkyl, $-CH_2$-aryl, a $-CH_2$-heterocyclic group or a $-CH_2$-substituted C_5 cycloalkyl, (optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is cyclobutyl or H;

R_5 is $-CH_2-O-CH_3$; and

R_8 is H or phenyl (optionally substituted with halo).

10. A compound according to claim 1, wherein

A is N;

B is $-CH_2-$;

G is oxygen;

R_1 is hydrogen;

R_2 is C_{1-10} alkyl, $-CH_2$-aryl or a $-CH_2$-heterocyclic group, (optionally substituted by one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

R_3 is hydrogen or cyclobutyl;

R_5 is one of the following 5-membered unsaturated heterocyclic ring structures:



;

R_6 is methyl, aralkyl, arylamino, aralkyl substituted by one or more halo and having a methylene group linking the aryl to the unsaturated 5-membered ring, aralkyl substituted by one or more halo and having an ethylene group linking the aryl to the unsaturated 5-membered ring; and

R_8 is phenyl,3,5-difluorophenyl or H.

11. A compound according to claim 1, having the formula:



12. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claims 1 to 11.

13. A compound in accordance with any one of claims 1 to 11 for use as a medicament.

14. Use of a compound in accordance with claims 1-11 in the manufacture of a medicament for the treatment of disorders caused by the malfunction of the acetylcholine or muscarinic systems.

15. The use of claim 14, wherein the disorder is Alzheimer's disease.

16. A method of treatment, prophylaxis and/or inhibition of disorders caused by the malfunction of the acetylcholine or muscarinic systems comprising the administration of a therapeutically effective amount of a compound as claimed in any of claims 1 to 11 to a subject in need thereof.

ABSTRACT

A compound of the formula:



or a pharmaceutically acceptable salt thereof, wherein:

A is CH or nitrogen;

B is $-CH_2-$, $-CHF-$, $-CF_2-$, NR_4 or O, with the proviso that when A is N, B is $-CH_2-$, $-CHF-$ or $-CF_2-$;

G is oxygen or =N-CN,

R_1 is hydrogen or C_{1-6} alkyl;

R_2 is hydrogen; C_{1-10} alkyl optionally substituted with C_{1-6} alkoxy or halogen; aralkyl, a $-CH_2$-heterocycle or a $-CH_2-C_5$ cycloalkyl ring each of which may be optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-8} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

R_3 is hydrogen; a cyclic alkyl radical containing from 3-6 carbon atoms or a C_1-C_6 alkyl;

R_4 is hydrogen or lower alkyl;

R_5 is a 5-membered unsaturated heterocyclic ring having one of the following structures:



where L and M are independently O or N (or NH where the circumstances require) with the proviso that both of L

and M cannot be O; Y is S, CH, O or N (or NH where the circumstances require); X is C or N; and

R_6 is lower alkyl; hydrogen; arylamino optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl; aralkyl optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl; or a group of formula:



wherein n is an integer in the range from 1 to 4 and HET is a heterocyclic group optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl;

or R_5 may also be C_2-C_4-aralkyl (e.g. CH_2-CH_2-phenyl), -CH_2-O-R_7 where R_7 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_2-C_4 aralkyl (e.g. CH_2-CH_2-phenyl) which groups may be optionally substituted with fluoro or hydroxy; and

R_8 is hydrogen or aryl (optionally substituted with one or more of halo, hydroxy, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{2-6} alkenyl, C_{2-6} haloalkenyl, C_{2-6} alkynyl or C_{2-6} haloalkynyl);

with the proviso that when either R_3 or R_8 is not hydrogen, the other is hydrogen.